[1] | EMADI A, GORE S D.Arsenic trioxide —— an old drug re-discovered[J]. Blood Rev, 2010, 24(4-5): 191-199. | [2] | ZHOU J.Arsenic trioxide: an ancient drug revived[J]. Chin Med J (Engl), 2012, 125(19): 3556-3560. | [3] | KIM E Y, LEE S S, SHIN J H, et al.Anticancer effect of arse-nic trioxide on cholangiocarcinoma: in vitro experiments and in vivo xenograft mouse model[J]. Clin Exp Med, 2014, 14(2): 215-224. | [4] | LEE J C, LEE H Y, MOON C H, et al.Arsenic trioxide as a vascular disrupting agent: synergistic effect with irinotecan on tumor growth delay in a CT26 allograft model[J]. Transl Oncol, 2013, 6(1): 83-91. | [5] | SIDES M D, SOSULSKI M L, LUO F, et al.Co-treatment with arsenic trioxide and ganciclovir reduces tumor volume in a murine xenograft model of nasopharyngeal carcinoma[J]. Vi-rol J, 2013, 10: 152. | [6] | HE X, YANG K, CHEN P, et al.Arsenic trioxide-based thera-py in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review[J]. Onco Targets Ther, 2014, 7: 1593-1599. | [7] | KERL K, MORENO N, HOLSTEN T, et al.Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1[J]. Int J Cancer, 2014, 135(4): 989-995. | [8] | CHEN W, ZHENG R, BAADE P D, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. | [9] | JIAO Y H, ZHANG Q, PAN L L, et al.Rat liver mitochondri-al dysfunction induced by an organic arsenical compound 4-(2-Nitrobenzaliminyl) phenyl arsenoxide[J]. J Membr Biol, 2015, 248(6): 1071-1078. | [10] | KITO M, AKAO Y, OHISHI N, et al.Arsenic trioxide-indu-ced apoptosis and its enhancement by buthionine sulfoximine in hepatocellular carcinoma cell lines[J]. Biochem Biophys Res Commun, 2002, 291(4): 861-867. | [11] | KITO M, MATSUMOTO K, WADA N, et al.Antitumor effect of arsenic trioxide in murine xenograft model[J]. Cancer Sci, 2003, 94(11): 1010-1014. | [12] | HUA H, QIN S, RUI J, et al.Pharmacokinetics of arsenic tri-oxide (As(2)O(3)) in Chinese primary hepatocarcinoma pa-tients[J]. Asian Pac J Cancer Prev, 2011, 12(1): 61-65. | [13] | XU H Y, YANG Y L, LIU S M, et al.Effect of arsenic trioxide on human hepatocarcinoma in nude mice[J]. World J Gastro-enterol, 2004, 10(24): 3677-3679. | [14] | YOO D R, CHONG S A, NAM M J.Proteome profiling of ar-senic trioxide-treated human hepatic cancer cells[J]. Cancer Genomics Proteomics, 2009, 6(5): 269-274. | [15] | ZHAO W, HU Y N, JIANG X J, et al.The apoptotic mecha-nism of hepatocellular carcinoma cell line (HepG2) induced by arsenic trioxide[J]. Sichuan Da Xue Xue Bao Yi Xue Ban, 2014, 45(5): 739-743. | [16] | 于浩, 姜洪磊, 许东, 等. 三氧化二砷对不同肝癌细胞系凋亡的影响[J]. 生物医学工程与临床, 2016(1): 83-86. | [17] | ALARIFI S, ALI D, ALKAHTANI S, et al.Arsenic trioxide-mediated oxidative stress and genotoxicity in human hepato-cellular carcinoma cells[J]. Onco Targets Ther, 2013, 6: 75-84. | [18] | ZHANG X, JIA S, YANG S, et al.Arsenic trioxide induces G2/M arrest in hepatocellular carcinoma cells by increasing the tumor suppressor PTEN expression[J]. J Cell Biochem, 2012, 113(11): 3528-3535. | [19] | JIANG F, WANG X, LIU Q, et al.Inhibition of TGF-beta/SMAD3/NF-kappaB signaling by microRNA-491 is involved in arsenic trioxide-induced anti-angiogenesis in hepatocellular carcinoma cells[J]. Toxicol Lett, 2014, 231(1): 55-61. | [20] | TUNG J N, ChENG Y W, HSU C H, et al. Normoxically overexpressed hypoxia inducible factor 1-alpha is involved in arsenic trioxide resistance acquisition in hepatocellular carci-noma[J]. Ann Surg Oncol, 2011, 18(5): 1492-1500. | [21] | ZhANG S, ZHOU J, ZHANG C, et al. Arsenic trioxide in-hibits HCCLM3 cells invasion through de novo ceramide syn-thesis and sphingomyelinase-induced ceramide production[J]. Med Oncol, 2012, 29(3): 2251-2260. | [22] | LI H Y, CAO L M.Inhibitory effect of arsenic trioxide on in-vasion in human hepatocellular carcinoma SMMC-7721 cells and its mechanism[J]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2012, 28(12): 1254-1257. | [23] | WANG X, JIANG F, MU J, et al.Arsenic trioxide attenu-ates the invasion potential of human liver cancer cells through the demethylation-activated microRNA-491[J]. Toxicol Lett,2014, 227(2): 75-83. | [24] | WANG G Z, ZHANG W, FANG Z T, et al.Arsenic trioxide:marked suppression of tumor metastasis potential by inhibit-ing the transcription factor Twist in vivo and in vitro[J]. J Cancer Res Clin Oncol, 2014, 140(7): 1125-1136. | [25] | 唐印华, 王玺, 梁桃, 等. As2O3抑制人肝癌细胞侵袭及转移的实验研究[J]. 哈尔滨医科大学学报, 2013(1): 24-27. | [26] | EAVES C J.Cancer stem cells: Here, there, everywhere[J]. Nature, 2008, 456(7222): 581-582. | [27] | BHOLA N E, BALKO J M, DUGGER T C, et al.TGF-beta inhibition enhances chemotherapy action against triple-nega-tive breast cancer[J]. J Clin Invest, 2013, 123(3): 1348-1358. | [28] | VIDAL S J, RODRIGUEZ-BRAVO V, GALSKY M, et al.Targeting cancer stem cells to suppress acquired chemotherapy resistance[J]. Oncogene, 2014, 33(36): 4451-4463. | [29] | ZHANG K Z, ZHANG Q B, ZHANG Q B, et al.Arsenic tri-oxide induces differentiation of CD133+ hepatocellular carci-noma cells and prolongs posthepatectomy survival by target-ing GLI1 expression in a mouse model[J]. J Hematol Oncol, 2014, 7: 28. | [30] | TOMULEASE C, SORITAU O, FISCHER-FOROR E, et al.Arsenic trioxide plus cisplatin/interferon alpha-2b/doxorubi-cin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma[J]. Hematol Oncol Stem Cell Ther, 2011, 4(2): 60-66. | [31] | LI Y, JIANG F, LIU Q, et al.Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the at-tenuation of endogenous transforming growth factor beta sig-nal[J]. Toxicol Sci, 2015, 143(1): 156-164. | [32] | ZHANG X, YANG X R, SUN C, et al.Promyelocytic leuke-mia protein induces arsenic trioxide resistance through regula-tion of aldehyde dehydrogenase 3 family member A1 in hepa-tocellular carcinoma[J]. Cancer Lett, 2015, 366(1): 112-122. | [33] | CHEN X, ZHANG M, LIU L X.The overexpression of mul-tidrug resistance-associated proteins and gankyrin contribute to arsenic trioxide resistance in liver and gastric cancer cells[J]. Oncol Rep, 2009, 22(1): 73-80. | [34] | Lin C C, Hsu C, Hsu C H, et al.Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial[J]. Invest New Drugs, 2007, 25(1): 77-84. | [35] | ZHENG T, YIN D, LU Z, et al.Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in hepatocellular carcinoma[J]. Mol Cancer, 2014, 13:133. | [36] | ARDALAN B, SUBBARAYAN P R, Ramos Y, et al.A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma[J]. Clin Cancer Res, 2010, 16(11): 3019-3027. | [37] | HAO L, ZHAO J, WANG X, et al.Hepatotoxicity from arse-nic trioxide for pediatric acute promyelocytic leukemia[J]. J Pediatr Hematol Oncol, 2013, 35(2): e67-e70. | [38] | JIAO Y H, ZHANG Q, PAN L L, et al.Rat liver mitochon-drial dysfunction induced by an organic arsenical com-pound 4-(2-Nitrobenzaliminyl) Phenyl Arsenoxide[J]. J Membr Biol, 2015, 248(6): 1071-1078. | [39] | ROSOMORDUC O, CHEVREAU C, DIELENSEGER P, et al.Use of sorafenib in patients with hepatocellular or renal carci-noma[J]. Gastroenterol Clin Biol, 2010, 34(3): 161-167. | [40] | SHAN J, SHEN J, LIU L, et al.Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma[J]. Hepatology, 2012, 56(3): 1004-1014. | [41] | BLIVET-VAN E M, CHETTOUH H, FARTOUX L, et al.Epidermal growth factor receptor and HER-3 restrict cell re-sponse to sorafenib in hepatocellular carcinoma cells[J]. J Hepatol, 2012, 57(1): 108-115. | [42] | CHEN H C, JENG Y M, YUAN R H, et al.SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocel-lular carcinoma and its expression predicts poor prognosis[J]. Ann Surg Oncol, 2012, 19(6): 2011-2019. | [43] | RANGWALA F, WILLIAMS K P, SMITH G R, et al.Differ-ential effects of arsenic trioxide on chemosensitization in hu-man hepatic tumor and stellate cell lines[J]. BMC Cancer, 2012, 12: 402. | [44] | YANG X, SUN D, TIAN Y, et al.Metformin sensitizes hepa-tocellular carcinoma to arsenic trioxide-induced apoptosis by downregulating Bcl2 expression[J]. Tumour Biol, 2015, 36(4): 2957-2964. | [45] | WEI J, YE C, LIU F, et al.All-trans retinoic acid and arsenic trioxide induce apoptosis and modulate intracellular concen-trations of calcium in hepatocellular carcinoma cells[J]. J Chemother, 2014, 26(6): 348-352. | [46] | 唐洁, 王川, 姜政. 水通道蛋白9表达水平影响HepG2肝癌细胞的生物学行为及对As2O3的敏感性[J]. 细胞与分子免疫学杂志, 2015, (6): 769-774. | [47] | CHEN C, ZHANG Y, WANG Y, et al.Synergic effect of 3’-azido-3’-deoxythymidine and arsenic trioxide in suppress-ing hepatoma cells[J]. Anticancer Drugs, 2011, 22(5): 435-443. | [48] | SHEN P, JIANG T, LU H, et al.Combination of Poly I: C and arsenic trioxide triggers apoptosis synergistically via activa-tion of TLR3 and mitochondrial pathways in hepatocellular carcinoma cells[J]. Cell Biol Int, 2011, 35(8): 803-810. | [49] | LUO Q, LI Y, DENG J, et al.PARP-1 inhibitor sensitizes ar-senic trioxide in hepatocellular carcinoma cells via abroga-tion of G2/M checkpoint and suppression of DNA damage re-pair[J]. Chem Biol Interact, 2015, 226: 12-22. | [50] | LUO Q, LI Y, LAI Y, et al.The role of NF-kappaB in PARP-inhibitor-mediated sensitization and detoxification of arsenic trioxide in hepatocellular carcinoma cells[J]. J Toxicol Sci,2015, 40(3): 349-363. | [51] | LIU Z M, TSENG J T, HONG D Y, et al.Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells[J]. Biochem J, 2011, 438(2): 349-358. | [52] | RABELLINO A, SCAGLIONI P P.PML degradation:multi-ple ways to eliminate PML[J]. Front Oncol, 2013, 3: 60. | [53] | ZHAO X Y, YANG S, CHEN Y R, et al.Resveratrol and arse-nic trioxide act synergistically to kill tumor cells in vitro and in vivo[J]. PLoS One, 2014, 9(6): e98925. | [54] | LI W, WANG M, WANG L, et al.Icariin synergizes with ar-senic trioxide to suppress human hepatocellular carcinoma[J]. Cell Biochem Biophys, 2014, 68(2): 427-436. | [55] | CHEN G, WANG K, YANG B Y, et al.Synergistic antitumor activity of oridonin and arsenic trioxide on hepatocellular car-cinoma cells[J]. Int J Oncol, 2012, 40(1): 139-147. | [56] | JIANG H, MA Y, CHEN X, et al.Genistein synergizes with arsenic trioxide to suppress human hepatocellular carcinoma[J]. Cancer Sci, 2010, 101(4): 975-983. | [57] | MA Y, WANG J, LIU L, et al.Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-kappaB[J]. Cancer Lett, 2011, 301(1): 75-84. | [58] | LIU L, CHEN B A, QIN S K.Anti-angiogenesis effect of ar-senic trioxide plus cinobufacin on human hepatocarcinoma transplantation model nude mice[J]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2011, 31(1): 67-72. | [59] | 倪珊珊, 廖广辉, 张广顺, 等. 三氧化二砷与隐丹参酮不同配比对人肝癌HepG2裸鼠移植瘤的抑制作用[J]. 浙江中医药大学学报, 2015(1): 62-66. | [60] | DIEPART C, KARROUM O, MAGAT J, et al.Arsenic triox-ide treatment decreases the oxygen consumption rate of tumor cells and radiosensitizes solid tumors[J]. Cancer Res, 2012,72(2): 482-490. | [61] | HINES-PERALTA A, SUKHATME V, REGAN M, et al.Im-proved tumor destruction with arsenic trioxide and radiofre-quency ablation in three animal models[J]. Radiology, 2006, 240(1): 82-89. | [62] | KIM H Y, PARK J W.Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and future[J]. Liver Cancer, 2014, 3(1): 9-17. | [63] | LI H, GONG J, JIANG X, et al.Arsenic trioxide treatment of rabbit liver VX-2 carcinoma via hepatic arterial cannulation-induced apoptosis and decreased levels of survivin in the tu-mor tissue[J]. Croat Med J, 2013, 54(1): 12-16. | [64] | WANG H, LIU Y, WANG X, et al.Randomized clinical con-trol study of locoregional therapy combined with arsenic tri-oxide for the treatment of hepatocellular carcinoma[J]. Cancer, 2015, 121(17): 2917-2925. | [65] | SEONG N J, YOON C J, KANG S G, et al.Effects of arsenic trioxide on radiofrequency ablation of VX2 liver tumor: intra-arterial versus intravenous administration[J]. Korean J Radiol. 2012, 13(2): 195-201. | [66] | KOLODKIN-GAL D, EDDEN Y, HARTSHTARK Z, et al.Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect[J]. Gene Ther, 2009, 16(7): 905-915. | [67] | 杨雅雯, 刘丹, 刘婷, 等. 三氧化二砷粉针剂联合重组腺病毒介导的IκBαM治疗肝癌[J]. 世界华人消化杂志, 2013(13): 1159-1163. | [68] | CUI L, ZHANG S, ZHANG W, et al.Arsenic trioxide and promyelocytic leukemia protein-adenovirus synergistically in-hibit in vitro and in vivo growth of a hepatoma cell line[J]. Oncol Res, 2010, 18(7): 305-314. | [69] | SRIVASTAVA S, RIEEDLL S R.Engineering CAR-T cells: Design concepts[J]. Trends Immunol, 2015, 36(8): 494-502. | [70] | GRUPP S A, KALOS M, BARRETT D, et al.Chimeric an-tigen receptor-modified T cells for acute lymphoid leukemia[J]. N Engl J Med, 2013, 368(16): 1509-1518. | [71] | GAO H, LI K, TU H, et al.Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma[J]. Clin Cancer Res, 2014, 20(24): 6418-6428. | [72] | ZHENG Y, DOU Y, DUAN L, et al.Using chemo-drugs or ir-radiation to break immune tolerance and facilitate immuno-therapy in solid cancer[J]. Cell Immunol, 2015, 294(1): 54-59. | [73] | LI F, GUO Z, LIZEE G, et al.Clinical prognostic value of CD4+CD25+FOXP3+regulatory T cells in peripheral blood of Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellu-lar carcinoma patients[J]. Clin Chem Lab Med, 2014, 52(9): 1357-1365. | [74] | HUANG Y, WANG F, WANG Y, et al.Intrahepatic interleu-kin-17+ T cells and FoxP3+ regulatory T cells cooperate topromote development and affect the prognosis of hepatocellu-lar carcinoma[J]. J Gastroenterol Hepatol, 2014, 29(4): 851-859. | [75] | THOMAS-SCHOEMANN A, BATTEUX F, MONGARET C, et al.Arsenic trioxide exerts antitumor activity through regu-latory T cell depletion mediated by oxidative stress in a mu-rine model of colon cancer[J]. J Immunol, 2012, 189(11): 5171-5177. | [76] | POWELL B L.Arsenic trioxide in acute promyelocytic leuke-mia: potion not poison[J]. Expert Rev Anticancer Ther, 2011, 11(9): 1317-1319. | [77] | RAO Y, LI R, ZHANG D.A drug from poison: how the ther-apeutic effect of arsenic trioxide on acute promyelocytic leu-kemia was discovered[J]. Sci China Life Sci, 2013, 56(6): 495-502. | [78] | LAU A, ZHENG Y, TAO S, et al.Arsenic inhibits autophagic flux, activating the Nrf2-Keap1 pathway in a p62-dependent manner[J]. Mol Cell Biol, 2013, 33(12): 2436-2446. | [79] | MIAO Z, WU L, LU M, et al.Analysis of the transcriptional regulation of cancer-related genes by aberrant DNA methyla-tion of the cis-regulation sites in the promoter region during hepatocyte carcinogenesis caused by arsenic[J]. Oncotarget, 2015, 6(25): 21493-21506. |
|